Steve Bryson, PhD,  science writer—

Off-label use of prostacyclin therapy successfully treated five newborns with persistent pulmonary hypertension of the neonate (PPHN), and switching from intravenous infusion to subcutaneous injection was well tolerated, a case series reported.  Its authors recommend larger studies to…

New variants in the DNA region that promote the activity of the BMPR2 gene — associated with familial pulmonary arterial hypertension (PAH) — lower the gene’s activity and may contribute to the condition in some families, a study…

Elevated levels of the protein IGFBP2 were identified in the blood of people with pulmonary arterial hypertension (PAH) and found to be associated with lower physical function, higher arterial blood pressure, and an increased mortality risk, a study reports.  …

For the first time, the long-term use of antipsychotic medications has been linked to the development of chronic thromboembolic pulmonary hypertension (CTEPH), a case study reports.  The authors recommend that CTEPH should be considered in patients who receive antipsychotics and also have symptoms associated…

Adults with chronic thromboembolic pulmonary hypertension (CTEPH) experience more breathing stoppages during sleep (apnea), lower blood oxygen, and higher levels of pro-inflammatory proteins in the blood than people with idiopathic pulmonary arterial hypertension who…

Volibris (ambrisentan) given to treat adults in China with pulmonary arterial hypertension (PAH) caused by connective tissue disease led to significant improvements in exercise capacity without signs of clinical worsening over 24 weeks, a study reported. Improvements were…

A case report found a patient’s pulmonary arterial hypertension (PAH) was caused by an undiagnosed case of the autoimmune disorder systemic sclerosis (SSc), highlighting the need for early and thorough diagnostic workups, researchers say. The 77-year-old woman’s PAH was also worsened by other conditions, including lung…

Tyvaso (inhaled treprostinil) significantly improved the exercise capacity of people with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD), achieving its primary endpoint in the…

Newborns were seen to be at an increased risk of pulmonary hypertension (PH) if they developed poorly while in the womb and had meconium aspiration syndrome, meaning they inhaled their feces during birth, a study from Pakistan reported.  The…

People with pulmonary arterial hypertension (PAH) who were treated with Uptravi (selexipag) had a lower risk and rate of hospitalization than those taking Orenitram (treprostinil), a real-world analysis revealed. The study,…

Newly published research has detailed the underlying biochemical process behind Acceleron Pharma’s investigational therapy sotatercept (ACE-011) for the potential treatment of people with pulmonary arterial hypertension (PAH). The findings, in two rat models of PAH,…

Newly identified mutations that contribute to a higher susceptibility of idiopathic pulmonary arterial hypertension (IPAH) in people from China, were found in a pathway commonly targeted by therapies that dilate blood vessels (vasodilators), a new study reports.  The authors suggested that screening for these mutations…